Skip to main content Accessibility help
×
Home

Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial

  • Dorte Eskesen (a1), Lillian Jespersen (a1), Birgit Michelsen (a1), Peter J. Whorwell (a2), Stefan Müller-Lissner (a3) and Cathrine M. Morberg (a1)...

Abstract

The aim of the present study was to investigate the effect of Bifidobacterium animalis subsp. lactis, BB-12®, on two primary end points – defecation frequency and gastrointestinal (GI) well-being – in healthy adults with low defecation frequency and abdominal discomfort. A total of 1248 subjects were included in a randomised, double-blind, placebo-controlled trial. After a 2-week run-in period, subjects were randomised to 1 or 10 billion colony-forming units/d of the probiotic strain BB-12® or a matching placebo capsule once daily for 4 weeks. Subjects completed a diary on bowel habits, relief of abdominal discomfort and symptoms. GI well-being, defined as global relief of abdominal discomfort, did not show significant differences. The OR for having a defecation frequency above baseline for ≥50 % of the time was 1·31 (95 % CI 0·98, 1·75), P=0·071, for probiotic treatment overall. Tightening the criteria for being a responder to an increase of ≥1 d/week for ≥50 % of the time resulted in an OR of 1·55 (95 % CI 1·22, 1·96), P=0·0003, for treatment overall. A treatment effect on average defecation frequency was found (P=0·0065), with the frequency being significantly higher compared with placebo at all weeks for probiotic treatment overall (all P<0·05). Effects on defecation frequency were similar for the two doses tested, suggesting that a ceiling effect was reached with the one billion dose. Overall, 4 weeks’ supplementation with the probiotic strain BB-12® resulted in a clinically relevant benefit on defecation frequency. The results suggest that consumption of BB-12® improves the GI health of individuals whose symptoms are not sufficiently severe to consult a doctor (ISRCTN18128385).

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial
      Available formats
      ×

Copyright

This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author

* Corresponding author: D. Eskesen, email dkdoe@chr-hansen.com

References

Hide All
1. Simren, M, Barbara, G, Flint, HJ, et al. (2013) Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62, 159176.
2. Ringel, Y & Carroll, I (2009) Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 19, 141150.
3. Lee, KN & Lee, OY (2014) Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 20, 88868897.
4. Bischoff, SC (2011) ‘Gut health’: a new objective in medicine? BMC Med 9, 24.
5. Konig, J & Brummer, RJ (2014) Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. Benef Microbes 5, 247261.
6. Ford, AC, Bercik, P, Morgan, DG, et al. (2014) Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. Aliment Pharmacol Ther 39, 312321.
7. Drossman, DA, Corazziari, E, et al. (2006) Rome III: The Functional Gastrointestinal Disorders, 3rd ed. McLean, VA: Degnon Associates.
8. Krogsgaard, LR, Engsbro, AL & Bytzer, P (2013) The epidemiology of irritable bowel syndrome in Denmark. A population-based survey in adults ≤50 years of age. Scand J Gastroenterol 48, 523529.
9. Canavan, C, West, J & Card, T (2014) The epidemiology of irritable bowel syndrome. Clin Epidemiol 6, 7180.
10. Canavan, C, West, J & Card, T (2014) Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther 40, 10231034.
11. Choung, RS, Branda, ME, Chitkara, D, et al. (2011) Longitudinal direct medical costs associated with constipation in women. Aliment Pharmacol Ther 33, 251260.
12. Choung, RS, Shah, ND, Chitkara, D, et al. (2011) Direct medical costs of constipation from childhood to early adulthood: a population-based birth cohort study. J Pediatr Gastroenterol Nutr 52, 4754.
13. Whitehead, WE & Drossman, DA (2010) Validation of symptom-based diagnostic criteria for irritable bowel syndrome: a critical review. Am J Gastroenterol 105, 814820.
14. European Food Safety Authority Panel on Dietetic Products, Nutrition and Allergies (2011) Guidance on the scientific requirements for health claims related to gut and immune function. EFSA J 9, 1984.
15. Trentacosti, AM, He, R, Burke, LB, et al. (2010) Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol 105, 731735.
16. Spiegel, BM, Hays, RD, Bolus, R, et al. (2014) Development of the NIH patient-reported outcomes measurement information system (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol 109, 18041814.
17. Irvine, EJ, Whitehead, WE, Chey, WD, et al. (2006) Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 130, 15381551.
18. European Agency for the Evaluation of Medicinal Products (2003) Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. London: European Agency for the Evaluation of Medicinal Products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003187.pdf
19. Nishida, S, Gotou, M, Akutsu, S, et al. (2004) Effect of yogurt containing Bifidobacterium lactis BB-12 on Improvement of defecation and fecal microflora of healthy female adults. Milk Science 53, 7180.
20. Pitkala, KH, Strandberg, TE, Finne Soveri, UH, et al. (2007) Fermented cereal with specific bifidobacteria normalizes bowel movements in elderly nursing home residents. A randomized, controlled trial. J Nutr Health Aging 11, 305311.
21. Uchida, K, Akashi, K, Kusunoki, I, et al. (2005) Effect of fermented milk containing Bifidobacterium lactis Bb-12 on stool frequency, defecation, fecal microbiota and safety of excessive ingestion in healthy female students – 2nd report. J Nutr Food 8, 3951.
22. Muller-Lissner, S, Koch, G, Talley, NJ, et al. (2003) Subject’s global assessment of relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 56, 310316.
23. Pimentel, M, Lembo, A, Chey, WD, et al. (2011) Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 364, 2232.
24. Hungin, AP, Mulligan, C, Pot, B, et al. (2013) Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice – an evidence-based international guide. Aliment Pharmacol Ther 38, 864886.
25. Guyonnet, D, Schlumberger, A, Mhamdi, L, et al. (2009) Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr 102, 16541662.
26. Marteau, P, Guyonnet, D, Lafaye de Micheaux, P, et al. (2013) A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms. Neurogastroenterol Motil 25, 331e252.
27. Craig, CL, Marshall, AL, Sjostrom, M, et al. (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35, 13811395.
28. Simren, M, Ohman, L, Olsson, J, et al. (2010) Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome – a randomized, double-blind, controlled study. Aliment Pharmacol Ther 31, 218227.
29. Holm, S (1979) A simple sequentially rejective multiple test procedure. Scand J Statist 6, 6570.
30. Corazziari, E, Bytzer, P, Delvaux, M, et al. (2003) Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 18, 569580.
31. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2012) Guidance for industry. Irritable bowel syndrome – clinical evaluation of drugs for treatment. http://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf (accessed February 2015).
32. European Medicines Agency, Committee for Medicinal Products for Human Use (2014) Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome.
33. Fedorak, RN, Vanner, SJ, Paterson, WG, et al. (2012) Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol 26, 252256.
34. Gupta, SK (2011) Intention-to-treat concept: a review. Perspect Clin Res 2, 109112.
35. Muller-Lissner, S (2013) Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol 9, 391401.
36. Meance, S, Cayuela, C, Raimondi, A, et al. (2003) Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis Strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microb Ecol Health Dis 15, 1522.
37. Larsen, CN, Nielsen, S, Kaestel, P, et al. (2006) Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. Eur J Clin Nutr 60, 12841293.
38. Whorwell, PJ, Altringer, L, Morel, J, et al. (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101, 15811590.
39. Ringel-Kulka, T, Palsson, OS, Maier, D, et al. (2011) Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders-a double-blind study. J Clin Gastroenterol 45, 518525.
40. Waller, PA, Gopal, PK, Leyer, GJ, et al. (2011) Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol 46, 10571064.
41. Ouwehand, AC, Donglian, C, Weijian, X, et al. (2014) Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine 32, 458463.
42. Gao, XW, Mubasher, M, Fang, CY, et al. (2010) Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 105, 16361641.
43. Saha, L (2014) Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol 20, 67596773.
44. Wall, GC, Bryant, GA, Bottenberg, MM, et al. (2014) Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol 20, 87968806.
45. Jadallah, KA, Kullab, SM & Sanders, DS (2014) Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol 20, 88988909.
46. Camilleri, M (2009) Editorial: is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome? Am J Gastroenterol 104, 920922.
47. Chang, L & Drossman, DA (2010) Rome Foundation Endpoints and Outcomes Conference 2009: optimizing clinical trials in FGID. Am J Gastroenterol 105, 722730.
48. Bellini, M, Gambaccini, D, Stasi, C, et al. (2014) Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol 20, 88078820.
49. Soares, RL (2014) Irritable bowel syndrome: a clinical review. World J Gastroenterol 20, 1214412160.

Keywords

Type Description Title
WORD
Supplementary materials

Eskesen supplementary material
Table S1-S4 and Figure S1-S2

 Word (763 KB)
763 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed